1887

Abstract

Cytomegalovirus (CMV) has evolved multiple immunological evasion strategies, including the encoding of viral interleukin (IL)-10 homologues (cmvIL-10). In this study, cmvIL-10 bound avidly to the same receptors on blood mononuclear cells and was as bio-potent as native human IL-10. Seventeen percent of plasma samples from 3200 Danish blood donors (corresponding to 28 % of the anti-CMV IgG-positive donors) contained substantial levels of anti-cmvIL-10 IgG antibodies, as measured by a radioimmunoassay for human anti-cmvIL-10 antibodies. The antibodies neither cross-reacted with native human IL-10 nor with Epstein–Barr virus-encoded IL-10. Anti-cmvIL-10 antibodies potently inhibited the binding of cmvIL-10 to cellular receptors, and they specifically inhibited cmvIL-10-induced JAK–STAT signalling. Ultimately, anti-cmvIL-10 antibodies blocked the inhibitory effect of cmvIL-10 on lipopolysaccharide-induced tumour necrosis factor alpha and IL-1β from blood mononuclear cells. Taken together, our data signify that cmvIL-10 has been produced during CMV infection, and that anti-cmvIL-10 IgG antibodies represent an effective immunological counter reaction against cmvIL-10.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.028738-0
2011-07-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/92/7/1508.html?itemId=/content/journal/jgv/10.1099/vir.0.028738-0&mimeType=html&fmt=ahah

References

  1. Bego M. G., St Jeor S. 2006; Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. Exp Hematol 34:555–570 [View Article][PubMed]
    [Google Scholar]
  2. Bendtzen K., Hansen M. B., Ross C., Svenson M. 2000; Detection of autoantibodies to cytokines. Mol Biotechnol 14:251–261 [View Article][PubMed]
    [Google Scholar]
  3. Cheung T. W., Teich S. A. 1999; Cytomegalovirus infection in patients with HIV infection. Mt Sinai J Med 66:113–124[PubMed]
    [Google Scholar]
  4. Couper K. N., Blount D. G., Riley E. M. 2008; IL-10: the master regulator of immunity to infection. J Immunol 180:5771–5777[PubMed] [CrossRef]
    [Google Scholar]
  5. Crough T., Khanna R. 2009; Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 22:76–98 [View Article][PubMed]
    [Google Scholar]
  6. de Lemos Rieper C., Galle P., Hansen M. B. 2009a; Characterization and potential clinical applications of autoantibodies against cytokines. Cytokine Growth Factor Rev 20:61–75 [View Article][PubMed]
    [Google Scholar]
  7. de Lemos Rieper C., Galle P., Svenson M., Pedersen B. K., Hansen M. B. 2009b; Preparation and validation of radio iodinated recombinant human IL-10 for the measurement of natural human antibodies against IL-10. J Immunol Methods 350:46–53 [View Article][PubMed]
    [Google Scholar]
  8. de Lemos Rieper C., Galle P., Pedersen B. K., Hansen M. B. 2010; A state of acquired IL-10 deficiency in 0.4% of Danish blood donors. Cytokine 51:286–293 [View Article][PubMed]
    [Google Scholar]
  9. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M. G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J. E. 1991; Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174:915–924 [View Article][PubMed]
    [Google Scholar]
  10. Drew W. L. 1988; Diagnosis of cytomegalovirus infection. Rev Infect Dis 10:Suppl 3S468–S476 [View Article][PubMed]
    [Google Scholar]
  11. Falagas M. E., Snydman D. R., Ruthazer R., Griffith J., Werner B. G., Freeman R., Rohrer R. 1997; Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 11:432–437[PubMed]
    [Google Scholar]
  12. Finlay B. B., McFadden G. 2006; Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124:767–782 [View Article][PubMed]
    [Google Scholar]
  13. Griffiths P. D., Walter S. 2005; Cytomegalovirus. Curr Opin Infect Dis 18:241–245 [View Article][PubMed]
    [Google Scholar]
  14. Hansen M. B., Svenson M., Abell K., Yasukawa K., Diamant M., Bendtzen K. 1995; Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur J Immunol 25:348–354 [View Article][PubMed]
    [Google Scholar]
  15. Hislop A. D., Taylor G. S., Sauce D., Rickinson A. B. 2007; Cellular responses to viral infection in humans: lessons from Epstein–Barr virus. Annu Rev Immunol 25:587–617 [View Article][PubMed]
    [Google Scholar]
  16. Jenkins C., Abendroth A., Slobedman B. 2004; A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol 78:1440–1447 [View Article][PubMed]
    [Google Scholar]
  17. Jenkins C., Garcia W., Abendroth A., Slobedman B. 2008; Expression of a human cytomegalovirus latency-associated homolog of interleukin-10 during the productive phase of infection. Virology 370:285–294 [View Article][PubMed]
    [Google Scholar]
  18. Jones B. C., Logsdon N. J., Josephson K., Cook J., Barry P. A., Walter M. R. 2002; Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc Natl Acad Sci U S A 99:9404–9409 [View Article][PubMed]
    [Google Scholar]
  19. Kanegane H., Wakiguchi H., Kanegane C., Kurashige T., Tosato G. 1997; Viral interleukin-10 in chronic active Epstein–Barr virus infection. J Infect Dis 176:254–257 [View Article][PubMed]
    [Google Scholar]
  20. Kano Y., Shiohara T. 2000; Current understanding of cytomegalovirus infection in immunocompetent individuals. J Dermatol Sci 22:196–204 [View Article][PubMed]
    [Google Scholar]
  21. Kotenko S. V., Saccani S., Izotova L. S., Mirochnitchenko O. V., Pestka S. 2000; Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A 97:1695–1700 [View Article][PubMed]
    [Google Scholar]
  22. Lehner P. J., Wilkinson G. W. 2001; Cytomegalovirus: from evasion to suppression?. Nat Immunol 2:993–994 [View Article][PubMed]
    [Google Scholar]
  23. Limaye A. P., Raghu G., Koelle D. M., Ferrenberg J., Huang M. L., Boeckh M. 2002; High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 185:20–27 [View Article][PubMed]
    [Google Scholar]
  24. Lin Y. L., Chang P. C., Wang Y., Li M. 2008; Identification of novel viral interleukin-10 isoforms of human cytomegalovirus AD169. Virus Res 131:213–223 [View Article][PubMed]
    [Google Scholar]
  25. Lockridge K. M., Zhou S. S., Kravitz R. H., Johnson J. L., Sawai E. T., Blewett E. L., Barry P. A. 2000; Primate cytomegaloviruses encode and express an IL-10-like protein. Virology 268:272–280 [View Article][PubMed]
    [Google Scholar]
  26. Menetrier-Caux C., Briere F., Jouvenne P., Peyron E., Peyron F., Banchereau J. 1996; Identification of human IgG autoantibodies specific for IL-10. Clin Exp Immunol 104:173–179 [View Article][PubMed]
    [Google Scholar]
  27. Moore K. W., Vieira P., Fiorentino D. F., Trounstine M. L., Khan T. A., Mosmann T. R. 1990; Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein–Barr virus gene BCRFI. Science 248:1230–1234 [View Article][PubMed]
    [Google Scholar]
  28. Moore K. W., de Waal Malefyt R., Coffman R. L., O'Garra A. 2001; Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765 [View Article][PubMed]
    [Google Scholar]
  29. Nigro G., Adler S. P., La Torre R., Best A. M. Congenital Cytomegalovirus Collaborating Group 2005; Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350–1362 [View Article][PubMed]
    [Google Scholar]
  30. Rowshani A. T., Bemelman F. J., van Leeuwen E. M., van Lier R. A., ten Berge I. J. 2005; Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 79:381–386 [View Article][PubMed]
    [Google Scholar]
  31. Salek-Ardakani S., Arrand J. R., Mackett M. 2002; Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV. Virology 304:342–351 [View Article][PubMed]
    [Google Scholar]
  32. Sinclair J. 2008; Human cytomegalovirus: Latency and reactivation in the myeloid lineage. J Clin Virol 41:180–185 [View Article][PubMed]
    [Google Scholar]
  33. Slobedman B., Barry P. A., Spencer J. V., Avdic S., Abendroth A. 2009; Virus-encoded homologs of cellular interleukin-10 and their control of host immune function. J Virol 83:9618–9629 [View Article][PubMed]
    [Google Scholar]
  34. Snydman D. R., Werner B. G., Heinze-Lacey B., Berardi V. P., Tilney N. L., Kirkman R. L., Milford E. L., Cho S. I., Bush H. L. Jr et al. 1987; Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317:1049–1054 [View Article][PubMed]
    [Google Scholar]
  35. Spencer J. V., Lockridge K. M., Barry P. A., Lin G., Tsang M., Penfold M. E., Schall T. J. 2002; Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 76:1285–1292 [View Article][PubMed]
    [Google Scholar]
  36. Spencer J. V., Cadaoas J., Castillo P. R., Saini V., Slobedman B. 2008; Stimulation of B lymphocytes by cmvIL-10 but not LAcmvIL-10. Virology 374:164–169 [View Article][PubMed]
    [Google Scholar]
  37. Tanner J. E., Diaz-Mitoma F., Rooney C. M., Alfieri C. 1997; Anti-interleukin-10 antibodies in patients with chronic active Epstein–Barr virus infection. J Infect Dis 176:1454–1461 [View Article][PubMed]
    [Google Scholar]
  38. Vancíková Z., Dvorák P. 2001; Cytomegalovirus infection in immunocompetent and immunocompromised individuals – a review. Curr Drug Targets Immune Endocr Metabol Disord 1:179–187 [View Article][PubMed]
    [Google Scholar]
  39. Yoon S. I., Jones B. C., Logsdon N. J., Walter M. R. 2005; Same structure, different function crystal structure of the Epstein–Barr virus IL-10 bound to the soluble IL-10R1 chain. Structure 13:551–564 [View Article][PubMed]
    [Google Scholar]
  40. Zdanov A. 2004; Structural features of the interleukin-10 family of cytokines. Curr Pharm Des 10:3873–3884 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.028738-0
Loading
/content/journal/jgv/10.1099/vir.0.028738-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error